Monday, November 13, 2006 7:00:00 AM PDT | VentureDeal Staff
MI -- Cerenis Therapeutics, an Ann Arbor-based
pharmaceutical company developing treatments for cardiovascular and metabolic
diseases, announced the closing of a $53.5 million Series B round of financing.
The round was led by TVM Capital and included OrbiMed and previous investors
Sofinnova Partners, Healthcap of Sweden, Alta Partners, EDF Ventures and NIF
SMBC Ventures of Japan.
Funding proceeds will go towards continued development of the company's
offerings in treating atherosclerosis.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
© VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.